ERBB2 and triple-negative breast carcinoma: The indication for NAC has been extended to human epidermal growth factor receptor 2 (HER2)-positive and triple-negative breast cancer (TNBC) with clinical T stage ≥ 2 or N stage ≥ 1 due to developments in molecular pathology and targeted therapy.